<table>
<thead>
<tr>
<th>Treatment</th>
<th>1st line</th>
<th>2nd line</th>
<th>3rd line</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conventional (chemotherapy)</td>
<td>154 (86%)</td>
<td>72 (42%)</td>
<td>26-89y</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Targeted</td>
<td>25 (14%)</td>
<td>99 (58%)</td>
<td>59.5y ± 12.9</td>
<td></td>
</tr>
</tbody>
</table>

Treatment strategies targeted (associated to chemotherapy):

- Cetuximab: 1.1% (1st line), 9.4% (2nd line), 15.6% (3rd line)
- Bevacizumab: 13.0% (1st line), 47.3% (2nd line), 84.4% (3rd line)

Conventional chemotherapy:

- 5FULV: 36.3% (1st line), 0.6% (2nd line), 8.3% (3rd line)
- XELOX: 25.7% (1st line), 37.4% (2nd line), 24.0% (3rd line)
- FOLFOX: 38.6% (1st line), 43.3% (2nd line), 47.0% (3rd line)
- FOLFIRI: 1.1% (1st line), 12.9% (2nd line), 5.2% (3rd line)
- FOLFOXIRI: - (1st line), 16.4% (2nd line), 1.1% (3rd line)
- XELIRI: - (1st line), 4.7% (2nd line), 34.4% (3rd line)

Cycles:

- ≤ 4 cycles: 16.8% (1st line), 15.6% (2nd line), 56.4% (3rd line)
- 5 - 6 cycles: 41.9% (1st line), 27.4% (2nd line), - (3rd line)
- 7 - 8 cycles: 19.0% (1st line), 30.7% (2nd line), - (3rd line)
- ≥ 9 cycles: 22.3% (1st line), 21.8% (2nd line), - (3rd line)

氟尿嘧啶/甲酰胺, FOLFOX = 芳氧氮芥、甲酰胺和奥沙利铂, XELOX = 卡培他滨和奥沙利铂, FOLFIRI = 埃克替尼、氟尿嘧啶、甲酰胺和奥沙利铂, FOLFOXIRI = 芳氧氮芥、甲酰胺、奥沙利铂和埃克替尼, XELIRI = 卡培他滨和埃克替尼。NS = 无显著差异。